nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—CYP3A4—Bexarotene—hematologic cancer	0.0435	0.0829	CbGbCtD
Salbutamol—CYP3A4—Lomustine—hematologic cancer	0.0404	0.0771	CbGbCtD
Salbutamol—CYP3A4—Busulfan—hematologic cancer	0.0404	0.0771	CbGbCtD
Salbutamol—CYP3A4—Thiotepa—hematologic cancer	0.036	0.0687	CbGbCtD
Salbutamol—CYP3A4—Methoxsalen—hematologic cancer	0.028	0.0534	CbGbCtD
Salbutamol—CYP3A4—Bortezomib—hematologic cancer	0.0267	0.0508	CbGbCtD
Salbutamol—CYP3A4—Daunorubicin—hematologic cancer	0.0255	0.0486	CbGbCtD
Salbutamol—CYP3A4—Cytarabine—hematologic cancer	0.0225	0.0429	CbGbCtD
Salbutamol—CYP3A4—Teniposide—hematologic cancer	0.0222	0.0422	CbGbCtD
Salbutamol—CYP3A4—Ifosfamide—hematologic cancer	0.0204	0.039	CbGbCtD
Salbutamol—CYP3A4—Imatinib—hematologic cancer	0.0195	0.0372	CbGbCtD
Salbutamol—CYP3A4—Ruxolitinib—hematologic cancer	0.0184	0.0351	CbGbCtD
Salbutamol—CYP3A4—Nilotinib—hematologic cancer	0.0177	0.0338	CbGbCtD
Salbutamol—CYP3A4—Vinorelbine—hematologic cancer	0.0176	0.0335	CbGbCtD
Salbutamol—CYP3A4—Triamcinolone—hematologic cancer	0.0161	0.0307	CbGbCtD
Salbutamol—CYP3A4—Dasatinib—hematologic cancer	0.0157	0.0299	CbGbCtD
Salbutamol—CYP3A4—Mitoxantrone—hematologic cancer	0.0155	0.0295	CbGbCtD
Salbutamol—CYP3A4—Betamethasone—hematologic cancer	0.0138	0.0263	CbGbCtD
Salbutamol—CYP3A4—Prednisolone—hematologic cancer	0.0136	0.026	CbGbCtD
Salbutamol—CYP3A4—Prednisone—hematologic cancer	0.0129	0.0245	CbGbCtD
Salbutamol—CYP3A4—Irinotecan—hematologic cancer	0.0122	0.0232	CbGbCtD
Salbutamol—CYP3A4—Vinblastine—hematologic cancer	0.0108	0.0207	CbGbCtD
Salbutamol—CYP3A4—Vincristine—hematologic cancer	0.0107	0.0203	CbGbCtD
Salbutamol—CYP3A4—Etoposide—hematologic cancer	0.00977	0.0186	CbGbCtD
Salbutamol—CYP3A4—Dexamethasone—hematologic cancer	0.00803	0.0153	CbGbCtD
Salbutamol—CYP3A4—Doxorubicin—hematologic cancer	0.00666	0.0127	CbGbCtD
Salbutamol—Isoprenaline—PIK3R1—hematologic cancer	0.00235	0.513	CrCbGaD
Salbutamol—Clenbuterol—TNF—hematologic cancer	0.00073	0.159	CrCbGaD
Salbutamol—Norepinephrine—SLC22A1—hematologic cancer	0.000469	0.102	CrCbGaD
Salbutamol—Epinephrine—SLC22A1—hematologic cancer	0.000426	0.0928	CrCbGaD
Salbutamol—Epinephrine—TNF—hematologic cancer	0.000307	0.0668	CrCbGaD
Salbutamol—Nadolol—ABCB1—hematologic cancer	0.000306	0.0665	CrCbGaD
Salbutamol—Arrhythmia—Epirubicin—hematologic cancer	4.35e-05	0.000101	CcSEcCtD
Salbutamol—Pain—Dexamethasone—hematologic cancer	4.34e-05	0.000101	CcSEcCtD
Salbutamol—Pain—Betamethasone—hematologic cancer	4.34e-05	0.000101	CcSEcCtD
Salbutamol—Nervous system disorder—Prednisone—hematologic cancer	4.34e-05	0.000101	CcSEcCtD
Salbutamol—Tachycardia—Prednisone—hematologic cancer	4.32e-05	0.0001	CcSEcCtD
Salbutamol—Skin disorder—Prednisone—hematologic cancer	4.29e-05	0.0001	CcSEcCtD
Salbutamol—Nausea—Gemcitabine—hematologic cancer	4.29e-05	9.99e-05	CcSEcCtD
Salbutamol—Vomiting—Cisplatin—hematologic cancer	4.28e-05	9.96e-05	CcSEcCtD
Salbutamol—Hyperhidrosis—Prednisone—hematologic cancer	4.27e-05	9.95e-05	CcSEcCtD
Salbutamol—Mental disorder—Epirubicin—hematologic cancer	4.26e-05	9.92e-05	CcSEcCtD
Salbutamol—Rash—Cisplatin—hematologic cancer	4.25e-05	9.88e-05	CcSEcCtD
Salbutamol—Dermatitis—Cisplatin—hematologic cancer	4.24e-05	9.87e-05	CcSEcCtD
Salbutamol—Malnutrition—Epirubicin—hematologic cancer	4.24e-05	9.86e-05	CcSEcCtD
Salbutamol—Diarrhoea—Etoposide—hematologic cancer	4.22e-05	9.82e-05	CcSEcCtD
Salbutamol—Anorexia—Prednisone—hematologic cancer	4.21e-05	9.81e-05	CcSEcCtD
Salbutamol—Ill-defined disorder—Methotrexate—hematologic cancer	4.2e-05	9.78e-05	CcSEcCtD
Salbutamol—Tinnitus—Doxorubicin—hematologic cancer	4.2e-05	9.77e-05	CcSEcCtD
Salbutamol—Feeling abnormal—Dexamethasone—hematologic cancer	4.18e-05	9.74e-05	CcSEcCtD
Salbutamol—Feeling abnormal—Betamethasone—hematologic cancer	4.18e-05	9.74e-05	CcSEcCtD
Salbutamol—Cardiac disorder—Doxorubicin—hematologic cancer	4.18e-05	9.73e-05	CcSEcCtD
Salbutamol—Flushing—Doxorubicin—hematologic cancer	4.18e-05	9.73e-05	CcSEcCtD
Salbutamol—Flatulence—Epirubicin—hematologic cancer	4.18e-05	9.72e-05	CcSEcCtD
Salbutamol—Tension—Epirubicin—hematologic cancer	4.16e-05	9.68e-05	CcSEcCtD
Salbutamol—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.15e-05	9.66e-05	CcSEcCtD
Salbutamol—Gastrointestinal pain—Betamethasone—hematologic cancer	4.15e-05	9.66e-05	CcSEcCtD
Salbutamol—Dysgeusia—Epirubicin—hematologic cancer	4.15e-05	9.66e-05	CcSEcCtD
Salbutamol—Hypersensitivity—Triamcinolone—hematologic cancer	4.12e-05	9.6e-05	CcSEcCtD
Salbutamol—Nervousness—Epirubicin—hematologic cancer	4.12e-05	9.58e-05	CcSEcCtD
Salbutamol—Back pain—Epirubicin—hematologic cancer	4.1e-05	9.54e-05	CcSEcCtD
Salbutamol—Angiopathy—Doxorubicin—hematologic cancer	4.09e-05	9.51e-05	CcSEcCtD
Salbutamol—Malaise—Methotrexate—hematologic cancer	4.08e-05	9.5e-05	CcSEcCtD
Salbutamol—Dizziness—Etoposide—hematologic cancer	4.08e-05	9.49e-05	CcSEcCtD
Salbutamol—Muscle spasms—Epirubicin—hematologic cancer	4.07e-05	9.48e-05	CcSEcCtD
Salbutamol—Immune system disorder—Doxorubicin—hematologic cancer	4.07e-05	9.47e-05	CcSEcCtD
Salbutamol—Vertigo—Methotrexate—hematologic cancer	4.07e-05	9.47e-05	CcSEcCtD
Salbutamol—Mediastinal disorder—Doxorubicin—hematologic cancer	4.06e-05	9.45e-05	CcSEcCtD
Salbutamol—Chills—Doxorubicin—hematologic cancer	4.04e-05	9.41e-05	CcSEcCtD
Salbutamol—Urticaria—Dexamethasone—hematologic cancer	4.03e-05	9.39e-05	CcSEcCtD
Salbutamol—Urticaria—Betamethasone—hematologic cancer	4.03e-05	9.39e-05	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.03e-05	9.38e-05	CcSEcCtD
Salbutamol—Dizziness—Prednisolone—hematologic cancer	4.02e-05	9.36e-05	CcSEcCtD
Salbutamol—Arrhythmia—Doxorubicin—hematologic cancer	4.02e-05	9.36e-05	CcSEcCtD
Salbutamol—Asthenia—Triamcinolone—hematologic cancer	4.01e-05	9.34e-05	CcSEcCtD
Salbutamol—Abdominal pain—Betamethasone—hematologic cancer	4.01e-05	9.34e-05	CcSEcCtD
Salbutamol—Abdominal pain—Dexamethasone—hematologic cancer	4.01e-05	9.34e-05	CcSEcCtD
Salbutamol—Body temperature increased—Betamethasone—hematologic cancer	4.01e-05	9.34e-05	CcSEcCtD
Salbutamol—Body temperature increased—Dexamethasone—hematologic cancer	4.01e-05	9.34e-05	CcSEcCtD
Salbutamol—Nausea—Cisplatin—hematologic cancer	4e-05	9.31e-05	CcSEcCtD
Salbutamol—Insomnia—Prednisone—hematologic cancer	4e-05	9.31e-05	CcSEcCtD
Salbutamol—Paraesthesia—Prednisone—hematologic cancer	3.97e-05	9.24e-05	CcSEcCtD
Salbutamol—Pruritus—Triamcinolone—hematologic cancer	3.96e-05	9.21e-05	CcSEcCtD
Salbutamol—Cough—Methotrexate—hematologic cancer	3.95e-05	9.2e-05	CcSEcCtD
Salbutamol—Mental disorder—Doxorubicin—hematologic cancer	3.95e-05	9.18e-05	CcSEcCtD
Salbutamol—Ill-defined disorder—Epirubicin—hematologic cancer	3.93e-05	9.15e-05	CcSEcCtD
Salbutamol—Vomiting—Etoposide—hematologic cancer	3.92e-05	9.13e-05	CcSEcCtD
Salbutamol—Malnutrition—Doxorubicin—hematologic cancer	3.92e-05	9.12e-05	CcSEcCtD
Salbutamol—Agitation—Epirubicin—hematologic cancer	3.89e-05	9.06e-05	CcSEcCtD
Salbutamol—Dyspepsia—Prednisone—hematologic cancer	3.89e-05	9.06e-05	CcSEcCtD
Salbutamol—Rash—Etoposide—hematologic cancer	3.89e-05	9.05e-05	CcSEcCtD
Salbutamol—Dermatitis—Etoposide—hematologic cancer	3.89e-05	9.04e-05	CcSEcCtD
Salbutamol—Headache—Etoposide—hematologic cancer	3.86e-05	8.99e-05	CcSEcCtD
Salbutamol—Flatulence—Doxorubicin—hematologic cancer	3.86e-05	8.99e-05	CcSEcCtD
Salbutamol—Arthralgia—Methotrexate—hematologic cancer	3.85e-05	8.97e-05	CcSEcCtD
Salbutamol—Chest pain—Methotrexate—hematologic cancer	3.85e-05	8.97e-05	CcSEcCtD
Salbutamol—Myalgia—Methotrexate—hematologic cancer	3.85e-05	8.97e-05	CcSEcCtD
Salbutamol—Tension—Doxorubicin—hematologic cancer	3.85e-05	8.95e-05	CcSEcCtD
Salbutamol—Decreased appetite—Prednisone—hematologic cancer	3.84e-05	8.95e-05	CcSEcCtD
Salbutamol—Dysgeusia—Doxorubicin—hematologic cancer	3.84e-05	8.94e-05	CcSEcCtD
Salbutamol—Rash—Prednisolone—hematologic cancer	3.84e-05	8.93e-05	CcSEcCtD
Salbutamol—Dermatitis—Prednisolone—hematologic cancer	3.83e-05	8.92e-05	CcSEcCtD
Salbutamol—Malaise—Epirubicin—hematologic cancer	3.82e-05	8.89e-05	CcSEcCtD
Salbutamol—Fatigue—Prednisone—hematologic cancer	3.81e-05	8.87e-05	CcSEcCtD
Salbutamol—Headache—Prednisolone—hematologic cancer	3.81e-05	8.87e-05	CcSEcCtD
Salbutamol—Discomfort—Methotrexate—hematologic cancer	3.81e-05	8.86e-05	CcSEcCtD
Salbutamol—Nervousness—Doxorubicin—hematologic cancer	3.81e-05	8.86e-05	CcSEcCtD
Salbutamol—Vertigo—Epirubicin—hematologic cancer	3.81e-05	8.86e-05	CcSEcCtD
Salbutamol—Syncope—Epirubicin—hematologic cancer	3.8e-05	8.84e-05	CcSEcCtD
Salbutamol—Back pain—Doxorubicin—hematologic cancer	3.79e-05	8.83e-05	CcSEcCtD
Salbutamol—Constipation—Prednisone—hematologic cancer	3.78e-05	8.8e-05	CcSEcCtD
Salbutamol—Muscle spasms—Doxorubicin—hematologic cancer	3.77e-05	8.77e-05	CcSEcCtD
Salbutamol—Palpitations—Epirubicin—hematologic cancer	3.74e-05	8.71e-05	CcSEcCtD
Salbutamol—Loss of consciousness—Epirubicin—hematologic cancer	3.72e-05	8.67e-05	CcSEcCtD
Salbutamol—Dizziness—Triamcinolone—hematologic cancer	3.7e-05	8.61e-05	CcSEcCtD
Salbutamol—Cough—Epirubicin—hematologic cancer	3.7e-05	8.61e-05	CcSEcCtD
Salbutamol—Anaphylactic shock—Methotrexate—hematologic cancer	3.7e-05	8.6e-05	CcSEcCtD
Salbutamol—Infection—Methotrexate—hematologic cancer	3.67e-05	8.54e-05	CcSEcCtD
Salbutamol—Nausea—Etoposide—hematologic cancer	3.66e-05	8.53e-05	CcSEcCtD
Salbutamol—Hypertension—Epirubicin—hematologic cancer	3.66e-05	8.51e-05	CcSEcCtD
Salbutamol—Feeling abnormal—Prednisone—hematologic cancer	3.64e-05	8.48e-05	CcSEcCtD
Salbutamol—Asthenia—Betamethasone—hematologic cancer	3.64e-05	8.48e-05	CcSEcCtD
Salbutamol—Asthenia—Dexamethasone—hematologic cancer	3.64e-05	8.48e-05	CcSEcCtD
Salbutamol—Ill-defined disorder—Doxorubicin—hematologic cancer	3.64e-05	8.47e-05	CcSEcCtD
Salbutamol—Nervous system disorder—Methotrexate—hematologic cancer	3.62e-05	8.43e-05	CcSEcCtD
Salbutamol—Gastrointestinal pain—Prednisone—hematologic cancer	3.62e-05	8.42e-05	CcSEcCtD
Salbutamol—Nausea—Prednisolone—hematologic cancer	3.61e-05	8.41e-05	CcSEcCtD
Salbutamol—Arthralgia—Epirubicin—hematologic cancer	3.61e-05	8.4e-05	CcSEcCtD
Salbutamol—Myalgia—Epirubicin—hematologic cancer	3.61e-05	8.4e-05	CcSEcCtD
Salbutamol—Chest pain—Epirubicin—hematologic cancer	3.61e-05	8.4e-05	CcSEcCtD
Salbutamol—Agitation—Doxorubicin—hematologic cancer	3.6e-05	8.39e-05	CcSEcCtD
Salbutamol—Anxiety—Epirubicin—hematologic cancer	3.59e-05	8.37e-05	CcSEcCtD
Salbutamol—Pruritus—Dexamethasone—hematologic cancer	3.59e-05	8.36e-05	CcSEcCtD
Salbutamol—Pruritus—Betamethasone—hematologic cancer	3.59e-05	8.36e-05	CcSEcCtD
Salbutamol—Skin disorder—Methotrexate—hematologic cancer	3.59e-05	8.35e-05	CcSEcCtD
Salbutamol—Hyperhidrosis—Methotrexate—hematologic cancer	3.57e-05	8.31e-05	CcSEcCtD
Salbutamol—Discomfort—Epirubicin—hematologic cancer	3.56e-05	8.3e-05	CcSEcCtD
Salbutamol—Vomiting—Triamcinolone—hematologic cancer	3.56e-05	8.28e-05	CcSEcCtD
Salbutamol—Malaise—Doxorubicin—hematologic cancer	3.54e-05	8.23e-05	CcSEcCtD
Salbutamol—Rash—Triamcinolone—hematologic cancer	3.53e-05	8.21e-05	CcSEcCtD
Salbutamol—Dry mouth—Epirubicin—hematologic cancer	3.53e-05	8.21e-05	CcSEcCtD
Salbutamol—Dermatitis—Triamcinolone—hematologic cancer	3.52e-05	8.2e-05	CcSEcCtD
Salbutamol—Vertigo—Doxorubicin—hematologic cancer	3.52e-05	8.2e-05	CcSEcCtD
Salbutamol—Anorexia—Methotrexate—hematologic cancer	3.52e-05	8.2e-05	CcSEcCtD
Salbutamol—Syncope—Doxorubicin—hematologic cancer	3.52e-05	8.18e-05	CcSEcCtD
Salbutamol—Urticaria—Prednisone—hematologic cancer	3.51e-05	8.18e-05	CcSEcCtD
Salbutamol—Headache—Triamcinolone—hematologic cancer	3.51e-05	8.16e-05	CcSEcCtD
Salbutamol—Body temperature increased—Prednisone—hematologic cancer	3.5e-05	8.14e-05	CcSEcCtD
Salbutamol—Abdominal pain—Prednisone—hematologic cancer	3.5e-05	8.14e-05	CcSEcCtD
Salbutamol—Diarrhoea—Betamethasone—hematologic cancer	3.47e-05	8.09e-05	CcSEcCtD
Salbutamol—Diarrhoea—Dexamethasone—hematologic cancer	3.47e-05	8.09e-05	CcSEcCtD
Salbutamol—Palpitations—Doxorubicin—hematologic cancer	3.46e-05	8.06e-05	CcSEcCtD
Salbutamol—Anaphylactic shock—Epirubicin—hematologic cancer	3.46e-05	8.05e-05	CcSEcCtD
Salbutamol—Oedema—Epirubicin—hematologic cancer	3.46e-05	8.05e-05	CcSEcCtD
Salbutamol—Hypotension—Methotrexate—hematologic cancer	3.45e-05	8.04e-05	CcSEcCtD
Salbutamol—Loss of consciousness—Doxorubicin—hematologic cancer	3.45e-05	8.02e-05	CcSEcCtD
Salbutamol—Infection—Epirubicin—hematologic cancer	3.44e-05	8e-05	CcSEcCtD
Salbutamol—Cough—Doxorubicin—hematologic cancer	3.42e-05	7.96e-05	CcSEcCtD
Salbutamol—Shock—Epirubicin—hematologic cancer	3.4e-05	7.92e-05	CcSEcCtD
Salbutamol—Nervous system disorder—Epirubicin—hematologic cancer	3.39e-05	7.89e-05	CcSEcCtD
Salbutamol—Hypertension—Doxorubicin—hematologic cancer	3.38e-05	7.88e-05	CcSEcCtD
Salbutamol—Tachycardia—Epirubicin—hematologic cancer	3.38e-05	7.86e-05	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.37e-05	7.84e-05	CcSEcCtD
Salbutamol—Skin disorder—Epirubicin—hematologic cancer	3.36e-05	7.82e-05	CcSEcCtD
Salbutamol—Dizziness—Dexamethasone—hematologic cancer	3.36e-05	7.81e-05	CcSEcCtD
Salbutamol—Dizziness—Betamethasone—hematologic cancer	3.36e-05	7.81e-05	CcSEcCtD
Salbutamol—Hyperhidrosis—Epirubicin—hematologic cancer	3.34e-05	7.78e-05	CcSEcCtD
Salbutamol—Insomnia—Methotrexate—hematologic cancer	3.34e-05	7.78e-05	CcSEcCtD
Salbutamol—Myalgia—Doxorubicin—hematologic cancer	3.34e-05	7.77e-05	CcSEcCtD
Salbutamol—Chest pain—Doxorubicin—hematologic cancer	3.34e-05	7.77e-05	CcSEcCtD
Salbutamol—Arthralgia—Doxorubicin—hematologic cancer	3.34e-05	7.77e-05	CcSEcCtD
Salbutamol—Anxiety—Doxorubicin—hematologic cancer	3.33e-05	7.74e-05	CcSEcCtD
Salbutamol—Nausea—Triamcinolone—hematologic cancer	3.32e-05	7.74e-05	CcSEcCtD
Salbutamol—Paraesthesia—Methotrexate—hematologic cancer	3.32e-05	7.72e-05	CcSEcCtD
Salbutamol—Discomfort—Doxorubicin—hematologic cancer	3.3e-05	7.68e-05	CcSEcCtD
Salbutamol—Anorexia—Epirubicin—hematologic cancer	3.3e-05	7.67e-05	CcSEcCtD
Salbutamol—Dyspnoea—Methotrexate—hematologic cancer	3.29e-05	7.67e-05	CcSEcCtD
Salbutamol—Somnolence—Methotrexate—hematologic cancer	3.29e-05	7.65e-05	CcSEcCtD
Salbutamol—Dry mouth—Doxorubicin—hematologic cancer	3.26e-05	7.6e-05	CcSEcCtD
Salbutamol—Hypersensitivity—Prednisone—hematologic cancer	3.26e-05	7.58e-05	CcSEcCtD
Salbutamol—Dyspepsia—Methotrexate—hematologic cancer	3.25e-05	7.57e-05	CcSEcCtD
Salbutamol—Hypotension—Epirubicin—hematologic cancer	3.23e-05	7.52e-05	CcSEcCtD
Salbutamol—Vomiting—Betamethasone—hematologic cancer	3.23e-05	7.51e-05	CcSEcCtD
Salbutamol—Vomiting—Dexamethasone—hematologic cancer	3.23e-05	7.51e-05	CcSEcCtD
Salbutamol—Decreased appetite—Methotrexate—hematologic cancer	3.21e-05	7.48e-05	CcSEcCtD
Salbutamol—Rash—Dexamethasone—hematologic cancer	3.2e-05	7.45e-05	CcSEcCtD
Salbutamol—Rash—Betamethasone—hematologic cancer	3.2e-05	7.45e-05	CcSEcCtD
Salbutamol—Anaphylactic shock—Doxorubicin—hematologic cancer	3.2e-05	7.45e-05	CcSEcCtD
Salbutamol—Oedema—Doxorubicin—hematologic cancer	3.2e-05	7.45e-05	CcSEcCtD
Salbutamol—Dermatitis—Betamethasone—hematologic cancer	3.2e-05	7.44e-05	CcSEcCtD
Salbutamol—Dermatitis—Dexamethasone—hematologic cancer	3.2e-05	7.44e-05	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.19e-05	7.43e-05	CcSEcCtD
Salbutamol—Fatigue—Methotrexate—hematologic cancer	3.19e-05	7.41e-05	CcSEcCtD
Salbutamol—Headache—Dexamethasone—hematologic cancer	3.18e-05	7.4e-05	CcSEcCtD
Salbutamol—Headache—Betamethasone—hematologic cancer	3.18e-05	7.4e-05	CcSEcCtD
Salbutamol—Infection—Doxorubicin—hematologic cancer	3.18e-05	7.4e-05	CcSEcCtD
Salbutamol—Asthenia—Prednisone—hematologic cancer	3.17e-05	7.38e-05	CcSEcCtD
Salbutamol—Pain—Methotrexate—hematologic cancer	3.16e-05	7.35e-05	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.15e-05	7.33e-05	CcSEcCtD
Salbutamol—Shock—Doxorubicin—hematologic cancer	3.15e-05	7.33e-05	CcSEcCtD
Salbutamol—Nervous system disorder—Doxorubicin—hematologic cancer	3.14e-05	7.3e-05	CcSEcCtD
Salbutamol—Pruritus—Prednisone—hematologic cancer	3.13e-05	7.28e-05	CcSEcCtD
Salbutamol—Insomnia—Epirubicin—hematologic cancer	3.13e-05	7.28e-05	CcSEcCtD
Salbutamol—Tachycardia—Doxorubicin—hematologic cancer	3.12e-05	7.27e-05	CcSEcCtD
Salbutamol—Skin disorder—Doxorubicin—hematologic cancer	3.11e-05	7.23e-05	CcSEcCtD
Salbutamol—Paraesthesia—Epirubicin—hematologic cancer	3.11e-05	7.23e-05	CcSEcCtD
Salbutamol—Hyperhidrosis—Doxorubicin—hematologic cancer	3.09e-05	7.2e-05	CcSEcCtD
Salbutamol—Dyspnoea—Epirubicin—hematologic cancer	3.08e-05	7.18e-05	CcSEcCtD
Salbutamol—Somnolence—Epirubicin—hematologic cancer	3.07e-05	7.16e-05	CcSEcCtD
Salbutamol—Anorexia—Doxorubicin—hematologic cancer	3.05e-05	7.1e-05	CcSEcCtD
Salbutamol—Feeling abnormal—Methotrexate—hematologic cancer	3.05e-05	7.09e-05	CcSEcCtD
Salbutamol—Dyspepsia—Epirubicin—hematologic cancer	3.04e-05	7.08e-05	CcSEcCtD
Salbutamol—Diarrhoea—Prednisone—hematologic cancer	3.03e-05	7.04e-05	CcSEcCtD
Salbutamol—Gastrointestinal pain—Methotrexate—hematologic cancer	3.02e-05	7.03e-05	CcSEcCtD
Salbutamol—Nausea—Dexamethasone—hematologic cancer	3.02e-05	7.02e-05	CcSEcCtD
Salbutamol—Nausea—Betamethasone—hematologic cancer	3.02e-05	7.02e-05	CcSEcCtD
Salbutamol—Decreased appetite—Epirubicin—hematologic cancer	3.01e-05	7e-05	CcSEcCtD
Salbutamol—Hypotension—Doxorubicin—hematologic cancer	2.99e-05	6.96e-05	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.99e-05	6.95e-05	CcSEcCtD
Salbutamol—Fatigue—Epirubicin—hematologic cancer	2.98e-05	6.94e-05	CcSEcCtD
Salbutamol—Pain—Epirubicin—hematologic cancer	2.96e-05	6.88e-05	CcSEcCtD
Salbutamol—Constipation—Epirubicin—hematologic cancer	2.96e-05	6.88e-05	CcSEcCtD
Salbutamol—Urticaria—Methotrexate—hematologic cancer	2.94e-05	6.83e-05	CcSEcCtD
Salbutamol—Dizziness—Prednisone—hematologic cancer	2.92e-05	6.81e-05	CcSEcCtD
Salbutamol—Abdominal pain—Methotrexate—hematologic cancer	2.92e-05	6.8e-05	CcSEcCtD
Salbutamol—Body temperature increased—Methotrexate—hematologic cancer	2.92e-05	6.8e-05	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.92e-05	6.78e-05	CcSEcCtD
Salbutamol—Insomnia—Doxorubicin—hematologic cancer	2.89e-05	6.74e-05	CcSEcCtD
Salbutamol—Paraesthesia—Doxorubicin—hematologic cancer	2.87e-05	6.69e-05	CcSEcCtD
Salbutamol—Dyspnoea—Doxorubicin—hematologic cancer	2.85e-05	6.64e-05	CcSEcCtD
Salbutamol—Feeling abnormal—Epirubicin—hematologic cancer	2.85e-05	6.63e-05	CcSEcCtD
Salbutamol—Somnolence—Doxorubicin—hematologic cancer	2.84e-05	6.62e-05	CcSEcCtD
Salbutamol—Gastrointestinal pain—Epirubicin—hematologic cancer	2.83e-05	6.58e-05	CcSEcCtD
Salbutamol—Dyspepsia—Doxorubicin—hematologic cancer	2.82e-05	6.56e-05	CcSEcCtD
Salbutamol—Vomiting—Prednisone—hematologic cancer	2.81e-05	6.54e-05	CcSEcCtD
Salbutamol—Rash—Prednisone—hematologic cancer	2.79e-05	6.49e-05	CcSEcCtD
Salbutamol—Dermatitis—Prednisone—hematologic cancer	2.79e-05	6.48e-05	CcSEcCtD
Salbutamol—Decreased appetite—Doxorubicin—hematologic cancer	2.78e-05	6.47e-05	CcSEcCtD
Salbutamol—Headache—Prednisone—hematologic cancer	2.77e-05	6.45e-05	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.76e-05	6.43e-05	CcSEcCtD
Salbutamol—Fatigue—Doxorubicin—hematologic cancer	2.76e-05	6.42e-05	CcSEcCtD
Salbutamol—Urticaria—Epirubicin—hematologic cancer	2.75e-05	6.39e-05	CcSEcCtD
Salbutamol—Pain—Doxorubicin—hematologic cancer	2.74e-05	6.37e-05	CcSEcCtD
Salbutamol—Constipation—Doxorubicin—hematologic cancer	2.74e-05	6.37e-05	CcSEcCtD
Salbutamol—Abdominal pain—Epirubicin—hematologic cancer	2.73e-05	6.36e-05	CcSEcCtD
Salbutamol—Body temperature increased—Epirubicin—hematologic cancer	2.73e-05	6.36e-05	CcSEcCtD
Salbutamol—Hypersensitivity—Methotrexate—hematologic cancer	2.72e-05	6.34e-05	CcSEcCtD
Salbutamol—Asthenia—Methotrexate—hematologic cancer	2.65e-05	6.17e-05	CcSEcCtD
Salbutamol—Feeling abnormal—Doxorubicin—hematologic cancer	2.64e-05	6.14e-05	CcSEcCtD
Salbutamol—Nausea—Prednisone—hematologic cancer	2.63e-05	6.11e-05	CcSEcCtD
Salbutamol—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.62e-05	6.09e-05	CcSEcCtD
Salbutamol—Pruritus—Methotrexate—hematologic cancer	2.61e-05	6.08e-05	CcSEcCtD
Salbutamol—Hypersensitivity—Epirubicin—hematologic cancer	2.55e-05	5.93e-05	CcSEcCtD
Salbutamol—Urticaria—Doxorubicin—hematologic cancer	2.54e-05	5.92e-05	CcSEcCtD
Salbutamol—Abdominal pain—Doxorubicin—hematologic cancer	2.53e-05	5.89e-05	CcSEcCtD
Salbutamol—Body temperature increased—Doxorubicin—hematologic cancer	2.53e-05	5.89e-05	CcSEcCtD
Salbutamol—Diarrhoea—Methotrexate—hematologic cancer	2.53e-05	5.88e-05	CcSEcCtD
Salbutamol—Asthenia—Epirubicin—hematologic cancer	2.48e-05	5.77e-05	CcSEcCtD
Salbutamol—Pruritus—Epirubicin—hematologic cancer	2.45e-05	5.69e-05	CcSEcCtD
Salbutamol—Dizziness—Methotrexate—hematologic cancer	2.44e-05	5.69e-05	CcSEcCtD
Salbutamol—Diarrhoea—Epirubicin—hematologic cancer	2.37e-05	5.51e-05	CcSEcCtD
Salbutamol—Hypersensitivity—Doxorubicin—hematologic cancer	2.36e-05	5.49e-05	CcSEcCtD
Salbutamol—Vomiting—Methotrexate—hematologic cancer	2.35e-05	5.47e-05	CcSEcCtD
Salbutamol—Rash—Methotrexate—hematologic cancer	2.33e-05	5.42e-05	CcSEcCtD
Salbutamol—Dermatitis—Methotrexate—hematologic cancer	2.33e-05	5.42e-05	CcSEcCtD
Salbutamol—Headache—Methotrexate—hematologic cancer	2.31e-05	5.39e-05	CcSEcCtD
Salbutamol—Asthenia—Doxorubicin—hematologic cancer	2.3e-05	5.34e-05	CcSEcCtD
Salbutamol—Dizziness—Epirubicin—hematologic cancer	2.29e-05	5.32e-05	CcSEcCtD
Salbutamol—Pruritus—Doxorubicin—hematologic cancer	2.26e-05	5.27e-05	CcSEcCtD
Salbutamol—Vomiting—Epirubicin—hematologic cancer	2.2e-05	5.12e-05	CcSEcCtD
Salbutamol—Nausea—Methotrexate—hematologic cancer	2.19e-05	5.11e-05	CcSEcCtD
Salbutamol—Diarrhoea—Doxorubicin—hematologic cancer	2.19e-05	5.1e-05	CcSEcCtD
Salbutamol—Rash—Epirubicin—hematologic cancer	2.18e-05	5.07e-05	CcSEcCtD
Salbutamol—Dermatitis—Epirubicin—hematologic cancer	2.18e-05	5.07e-05	CcSEcCtD
Salbutamol—Headache—Epirubicin—hematologic cancer	2.17e-05	5.04e-05	CcSEcCtD
Salbutamol—Dizziness—Doxorubicin—hematologic cancer	2.12e-05	4.92e-05	CcSEcCtD
Salbutamol—Nausea—Epirubicin—hematologic cancer	2.05e-05	4.78e-05	CcSEcCtD
Salbutamol—Vomiting—Doxorubicin—hematologic cancer	2.03e-05	4.73e-05	CcSEcCtD
Salbutamol—Rash—Doxorubicin—hematologic cancer	2.02e-05	4.7e-05	CcSEcCtD
Salbutamol—Dermatitis—Doxorubicin—hematologic cancer	2.02e-05	4.69e-05	CcSEcCtD
Salbutamol—Headache—Doxorubicin—hematologic cancer	2e-05	4.67e-05	CcSEcCtD
Salbutamol—Nausea—Doxorubicin—hematologic cancer	1.9e-05	4.42e-05	CcSEcCtD
Salbutamol—ADRB2—Signaling Pathways—PARP1—hematologic cancer	1.54e-05	0.000374	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HDAC2—hematologic cancer	1.52e-05	0.000369	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCR4—hematologic cancer	1.52e-05	0.000369	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FBXW7—hematologic cancer	1.51e-05	0.000368	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CDA—hematologic cancer	1.49e-05	0.000362	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HDAC2—hematologic cancer	1.48e-05	0.000361	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCR4—hematologic cancer	1.48e-05	0.000361	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CBL—hematologic cancer	1.48e-05	0.00036	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL3—hematologic cancer	1.46e-05	0.000356	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CBL—hematologic cancer	1.45e-05	0.000352	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CG—hematologic cancer	1.44e-05	0.000352	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTPN1—hematologic cancer	1.44e-05	0.00035	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PC—hematologic cancer	1.43e-05	0.000349	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL3—hematologic cancer	1.43e-05	0.000348	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PTPN11—hematologic cancer	1.42e-05	0.000345	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RASGRP1—hematologic cancer	1.41e-05	0.000344	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CG—hematologic cancer	1.41e-05	0.000344	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HSP90AA1—hematologic cancer	1.41e-05	0.000343	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SYK—hematologic cancer	1.41e-05	0.000343	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTPN1—hematologic cancer	1.41e-05	0.000342	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CD—hematologic cancer	1.4e-05	0.00034	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PTPN11—hematologic cancer	1.39e-05	0.000338	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RASGRP1—hematologic cancer	1.38e-05	0.000337	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GBA—hematologic cancer	1.38e-05	0.000337	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC35B2—hematologic cancer	1.38e-05	0.000337	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SYK—hematologic cancer	1.38e-05	0.000336	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HSP90AA1—hematologic cancer	1.38e-05	0.000336	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CREB1—hematologic cancer	1.37e-05	0.000335	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CD—hematologic cancer	1.37e-05	0.000333	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—STAT1—hematologic cancer	1.36e-05	0.000331	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CCL2—hematologic cancer	1.35e-05	0.000327	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CREB1—hematologic cancer	1.34e-05	0.000327	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6R—hematologic cancer	1.34e-05	0.000326	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—STAT1—hematologic cancer	1.33e-05	0.000324	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3R1—hematologic cancer	1.32e-05	0.000321	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CCL2—hematologic cancer	1.32e-05	0.00032	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6R—hematologic cancer	1.31e-05	0.000319	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3R1—hematologic cancer	1.29e-05	0.000314	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—JAK2—hematologic cancer	1.28e-05	0.000312	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—MAP2K1—hematologic cancer	1.28e-05	0.000311	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GRB2—hematologic cancer	1.27e-05	0.00031	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CD—hematologic cancer	1.27e-05	0.000309	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PDGFA—hematologic cancer	1.27e-05	0.000309	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MTAP—hematologic cancer	1.26e-05	0.000308	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—JAK2—hematologic cancer	1.26e-05	0.000306	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KITLG—hematologic cancer	1.25e-05	0.000304	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MAP2K1—hematologic cancer	1.25e-05	0.000304	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GRB2—hematologic cancer	1.24e-05	0.000303	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CD—hematologic cancer	1.24e-05	0.000302	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PDGFA—hematologic cancer	1.24e-05	0.000302	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KITLG—hematologic cancer	1.22e-05	0.000298	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—STAT5A—hematologic cancer	1.22e-05	0.000298	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CB—hematologic cancer	1.22e-05	0.000297	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CDKN2B—hematologic cancer	1.21e-05	0.000295	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3R1—hematologic cancer	1.2e-05	0.000292	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—STAT5A—hematologic cancer	1.2e-05	0.000291	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CB—hematologic cancer	1.19e-05	0.00029	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CDKN2B—hematologic cancer	1.19e-05	0.000288	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3R1—hematologic cancer	1.17e-05	0.000286	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CD86—hematologic cancer	1.17e-05	0.000285	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—JAK2—hematologic cancer	1.17e-05	0.000284	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HES1—hematologic cancer	1.16e-05	0.000281	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NCOR1—hematologic cancer	1.15e-05	0.00028	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CD86—hematologic cancer	1.15e-05	0.000279	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—JAK2—hematologic cancer	1.14e-05	0.000277	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CSF2—hematologic cancer	1.14e-05	0.000277	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGF1—hematologic cancer	1.14e-05	0.000277	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HES1—hematologic cancer	1.13e-05	0.000275	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—FHL2—hematologic cancer	1.13e-05	0.000274	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NCOR1—hematologic cancer	1.12e-05	0.000274	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FOXO1—hematologic cancer	1.12e-05	0.000273	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—IL2—hematologic cancer	1.12e-05	0.000272	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PDGFRB—hematologic cancer	1.12e-05	0.000272	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CSF2—hematologic cancer	1.11e-05	0.000271	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGF1—hematologic cancer	1.11e-05	0.000271	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CB—hematologic cancer	1.11e-05	0.000269	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AGRN—hematologic cancer	1.11e-05	0.000269	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PDGFRA—hematologic cancer	1.1e-05	0.000268	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PRKCG—hematologic cancer	1.1e-05	0.000267	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—JAK1—hematologic cancer	1.1e-05	0.000267	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FOXO1—hematologic cancer	1.1e-05	0.000267	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—IL2—hematologic cancer	1.09e-05	0.000267	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PDGFRB—hematologic cancer	1.09e-05	0.000266	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CB—hematologic cancer	1.08e-05	0.000264	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PDGFRA—hematologic cancer	1.08e-05	0.000262	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PRKCG—hematologic cancer	1.07e-05	0.000261	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—JAK1—hematologic cancer	1.07e-05	0.000261	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HMMR—hematologic cancer	1.05e-05	0.000255	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—IDH2—hematologic cancer	1.05e-05	0.000255	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL2RA—hematologic cancer	1.02e-05	0.000249	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL2—hematologic cancer	1.02e-05	0.000247	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TERT—hematologic cancer	1.01e-05	0.000247	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL2RA—hematologic cancer	1e-05	0.000244	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL2—hematologic cancer	9.94e-06	0.000242	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TERT—hematologic cancer	9.91e-06	0.000241	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PDGFB—hematologic cancer	9.88e-06	0.000241	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ARNTL—hematologic cancer	9.85e-06	0.00024	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PDGFB—hematologic cancer	9.67e-06	0.000235	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TSC2—hematologic cancer	9.66e-06	0.000235	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ACP5—hematologic cancer	9.59e-06	0.000233	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CA9—hematologic cancer	9.59e-06	0.000233	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NCOR2—hematologic cancer	9.46e-06	0.00023	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TSC2—hematologic cancer	9.45e-06	0.00023	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGFR3—hematologic cancer	9.29e-06	0.000226	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAPK14—hematologic cancer	9.2e-06	0.000224	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGFR3—hematologic cancer	9.09e-06	0.000221	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ESR1—hematologic cancer	9.03e-06	0.00022	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—IDH1—hematologic cancer	9.01e-06	0.000219	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAPK14—hematologic cancer	9e-06	0.000219	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FN1—hematologic cancer	8.92e-06	0.000217	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TXN—hematologic cancer	8.91e-06	0.000217	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCC3—hematologic cancer	8.91e-06	0.000217	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTO1—hematologic cancer	8.91e-06	0.000217	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ESR1—hematologic cancer	8.83e-06	0.000215	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—BAD—hematologic cancer	8.81e-06	0.000214	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NFKBIA—hematologic cancer	8.81e-06	0.000214	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOTCH1—hematologic cancer	8.72e-06	0.000212	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FN1—hematologic cancer	8.72e-06	0.000212	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SPHK1—hematologic cancer	8.72e-06	0.000212	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—BAD—hematologic cancer	8.62e-06	0.00021	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NFKBIA—hematologic cancer	8.62e-06	0.00021	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CD80—hematologic cancer	8.55e-06	0.000208	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOTCH1—hematologic cancer	8.53e-06	0.000208	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CG—hematologic cancer	8.53e-06	0.000208	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KIT—hematologic cancer	8.53e-06	0.000208	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—NRAS—hematologic cancer	8.53e-06	0.000208	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTPN11—hematologic cancer	8.38e-06	0.000204	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—UGT1A1—hematologic cancer	8.38e-06	0.000204	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CD80—hematologic cancer	8.36e-06	0.000204	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CG—hematologic cancer	8.35e-06	0.000203	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KIT—hematologic cancer	8.35e-06	0.000203	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—NRAS—hematologic cancer	8.35e-06	0.000203	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTPN11—hematologic cancer	8.2e-06	0.0002	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—MAPK3—hematologic cancer	8.17e-06	0.000199	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CRABP1—hematologic cancer	8.15e-06	0.000198	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC22A1—hematologic cancer	8.15e-06	0.000198	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CREB1—hematologic cancer	8.12e-06	0.000198	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—BRAF—hematologic cancer	8.02e-06	0.000195	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MAPK3—hematologic cancer	7.99e-06	0.000195	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCL2—hematologic cancer	7.95e-06	0.000193	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CREB1—hematologic cancer	7.94e-06	0.000193	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALOX5—hematologic cancer	7.94e-06	0.000193	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6R—hematologic cancer	7.92e-06	0.000193	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CREBBP—hematologic cancer	7.91e-06	0.000193	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—BRAF—hematologic cancer	7.85e-06	0.000191	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCL2—hematologic cancer	7.77e-06	0.000189	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6R—hematologic cancer	7.75e-06	0.000189	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CREBBP—hematologic cancer	7.74e-06	0.000188	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NUP98—hematologic cancer	7.69e-06	0.000187	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAP2K1—hematologic cancer	7.55e-06	0.000184	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CD—hematologic cancer	7.5e-06	0.000183	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ADCY7—hematologic cancer	7.47e-06	0.000182	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NCOA3—hematologic cancer	7.47e-06	0.000182	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CA—hematologic cancer	7.43e-06	0.000181	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NUP214—hematologic cancer	7.42e-06	0.000181	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	7.39e-06	0.00018	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	7.34e-06	0.000179	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	7.34e-06	0.000179	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	7.27e-06	0.000177	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCG2—hematologic cancer	7.26e-06	0.000177	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MTR—hematologic cancer	7.26e-06	0.000177	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	7.18e-06	0.000175	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGF2—hematologic cancer	7.18e-06	0.000175	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ENO2—hematologic cancer	7.12e-06	0.000173	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	7.08e-06	0.000172	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGF2—hematologic cancer	7.03e-06	0.000171	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	6.93e-06	0.000169	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTT1—hematologic cancer	6.91e-06	0.000168	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—JAK2—hematologic cancer	6.88e-06	0.000168	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SDC1—hematologic cancer	6.75e-06	0.000164	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	6.75e-06	0.000164	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—JAK2—hematologic cancer	6.73e-06	0.000164	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MDM2—hematologic cancer	6.72e-06	0.000164	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	6.6e-06	0.000161	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MDM2—hematologic cancer	6.57e-06	0.00016	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MTOR—hematologic cancer	6.54e-06	0.000159	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	6.54e-06	0.000159	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	6.4e-06	0.000156	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MTOR—hematologic cancer	6.4e-06	0.000156	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	6.24e-06	0.000152	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	6.14e-06	0.000149	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	6.11e-06	0.000149	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	6.07e-06	0.000148	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CASP3—hematologic cancer	6.01e-06	0.000146	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL2—hematologic cancer	6e-06	0.000146	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	6e-06	0.000146	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6—hematologic cancer	5.97e-06	0.000145	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	5.94e-06	0.000145	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CASP3—hematologic cancer	5.88e-06	0.000143	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL2—hematologic cancer	5.87e-06	0.000143	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCND1—hematologic cancer	5.85e-06	0.000142	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6—hematologic cancer	5.84e-06	0.000142	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—JUN—hematologic cancer	5.84e-06	0.000142	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CD44—hematologic cancer	5.74e-06	0.00014	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NQO1—hematologic cancer	5.74e-06	0.00014	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCND1—hematologic cancer	5.73e-06	0.000139	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—JUN—hematologic cancer	5.71e-06	0.000139	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	5.66e-06	0.000138	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTEN—hematologic cancer	5.65e-06	0.000138	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	5.54e-06	0.000135	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	5.53e-06	0.000135	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTEN—hematologic cancer	5.53e-06	0.000135	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	5.51e-06	0.000134	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYCS—hematologic cancer	5.43e-06	0.000132	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	5.41e-06	0.000132	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	5.4e-06	0.000131	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	5.39e-06	0.000131	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EP300—hematologic cancer	5.39e-06	0.000131	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EP300—hematologic cancer	5.27e-06	0.000128	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SRC—hematologic cancer	5.24e-06	0.000128	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SRC—hematologic cancer	5.12e-06	0.000125	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	5.1e-06	0.000124	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—STAT3—hematologic cancer	5.05e-06	0.000123	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NRAS—hematologic cancer	5.04e-06	0.000123	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	4.99e-06	0.000122	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—STAT3—hematologic cancer	4.94e-06	0.00012	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NRAS—hematologic cancer	4.93e-06	0.00012	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	4.83e-06	0.000118	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTP1—hematologic cancer	4.79e-06	0.000117	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	4.72e-06	0.000115	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MYC—hematologic cancer	4.69e-06	0.000114	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	4.68e-06	0.000114	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MYC—hematologic cancer	4.59e-06	0.000112	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	4.58e-06	0.000112	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCB1—hematologic cancer	4.53e-06	0.00011	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NCOR1—hematologic cancer	4.4e-06	0.000107	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTM1—hematologic cancer	4.4e-06	0.000107	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KRAS—hematologic cancer	4.34e-06	0.000106	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KRAS—hematologic cancer	4.24e-06	0.000103	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	3.99e-06	9.7e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	3.9e-06	9.49e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MTHFR—hematologic cancer	3.89e-06	9.47e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TP53—hematologic cancer	3.86e-06	9.39e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TP53—hematologic cancer	3.77e-06	9.18e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HRAS—hematologic cancer	3.69e-06	8.98e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HRAS—hematologic cancer	3.61e-06	8.78e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6—hematologic cancer	3.53e-06	8.59e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6—hematologic cancer	3.45e-06	8.4e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CG—hematologic cancer	3.27e-06	7.96e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKT1—hematologic cancer	3.26e-06	7.93e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKT1—hematologic cancer	3.18e-06	7.75e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CREBBP—hematologic cancer	3.03e-06	7.38e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.87e-06	6.99e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALB—hematologic cancer	2.84e-06	6.9e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.71e-06	6.6e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CB—hematologic cancer	2.5e-06	6.1e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTEN—hematologic cancer	2.16e-06	5.27e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—EP300—hematologic cancer	2.06e-06	5.02e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.53e-06	3.72e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AKT1—hematologic cancer	1.25e-06	3.04e-05	CbGpPWpGaD
